Ikarovec

Ikarovec was formed as a spin-out from the biotechnology company Quethera, which was acquired by Astellas Pharmaceuticals in 2018. Our technology allows for targeting multiple disease targets and pathways thereby improving efficacy and restoring sight and preventing blindness. Gene therapy is a technique which allows DNA to be introduced into target cells in the eye through a process called gene transfer. The DNA contains information which instructs the target cells in the eye to make proteins which can then treat a particular disease.